Ciprofloxacin Kit
NDC 62135-393
Kit
Product Information
Ciprofloxacin is a ANDA-approved product labeled by Chartwell Rx, Llc. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a kit. This product entry covers the primary NDC 62135-393 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
NDC Product Code:
62135-393
Proprietary Name:
Ciprofloxacin
Non-Proprietary Name: [1]
Ciprofloxacin
NDC Directory Status:
Human Prescription Drug
Product Type: [3]
ACTIVE PRODUCT INCLUDED in the NDC Directory
Code Navigator:
Clinical Specifications
Dosage Form:
Kit
- A packaged collection of related material.
Labeler & Regulatory Data
Labeler Name: [5]
Labeler Code:
62135
Product Label ID:
FDA Application Number: [6]
ANDA200563
Marketing Category: [8]
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Marketing Timeline
Start Marketing Date: [9]
03-05-2014
Listing Expiration Date: [11]
12-31-2027
Exclude Flag: [12]
N
Code Structure Chart
Product Details
What is NDC 62135-393?
The NDC code 62135-393 is assigned by the FDA to the product Ciprofloxacin. This pharmaceutical product is labeled by Chartwell Rx, Llc and is currently categorized as listed product. The medication is a kit. In terms of distribution, this product is available in a single package configuration. The associated package NDC(s) include: 62135-393-42. Beyond standard identification, this entry provides technical data including pharmacologic classes, UNII ingredient references, and RxNorm cross-referencing for healthcare systems.
What are the uses of this product?
Ciprofloxacin Oral Suspension is supplied in 5% (5 g ciprofloxacin in 100 mL) and 10% (10 g ciprofloxacin in 100 mL) strengths. Ciprofloxacin for Oral Suspension is composed of two components (granular blend and diluent) that must be combined prior to dispensing.Table 5: Appropriate Dosing Volumes of the Reconstituted Oral SuspensionsDose5%(250 mg/5 mL)10%(500 mg/5 mL)250 mg5 mL2.5 mL500 mg10 mL5 mL750 mg15 mL7.5 mLPreparation of the suspension:Step 1:The small bottle contains the granular blend and the large bottle contains the diluent. Shake the diluent bottle for about 30 seconds.Step 2:Open the bottles containing granular blend and the diluent. Child-proof cap: Press down according to instructions on the cap while turning to the left. Step 3:Pour the granular blend completely into the larger bottle of diluent.
Do not add water to the suspension.Step 4:Remove the top layer of the diluent bottle label (to reveal the Ciprofloxacin for Oral Suspension, USP label). Close the large bottle tightly. Shake vigorously for about 30 seconds to form uniform dispersion. The suspension is ready for use.Step 5:Write the expiration date of the re-constituted oral suspension on the bottle label.Reconstituted product may be stored below 30°C (86°F) for 14 days. Protect from freezing.No additions should be made to the mixed final ciprofloxacin suspension. Ciprofloxacin for Oral Suspension should not be administered through feeding or NG (nasogastric) tubes due to its physical characteristics.
What is the NDC to RxNorm Crosswalk for this product?
RxNorm is a normalized naming system for generic and branded drugs that assigns unique concept identifier(s) known as RxCUIs to NDC products.The NDC to RxNorm Crosswalk for this produdct indicates multiple concept unique identifiers (RXCUIs) are associated with this product:
- RxCUI: 309308 - ciprofloxacin 250 MG in 5 mL Oral Suspension
- RxCUI: 309308 - ciprofloxacin 50 MG/ML Oral Suspension
- RxCUI: 309308 - ciprofloxacin 250 MG per 5 ML Oral Suspension
- RxCUI: 309310 - ciprofloxacin 500 MG in 5 mL Oral Suspension
- RxCUI: 309310 - ciprofloxacin 100 MG/ML Oral Suspension
* Please review the full disclaimer at the bottom of this page.
Product & Regulatory Definitions
What is the Non-Proprietary Name? The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
What kind of product is this? Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
What is the Labeler Name? Name of Company corresponding to the labeler code segment of the Product NDC.
What is the FDA Application Number? This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
What is the Marketing Category? Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
What is the Start Marketing Date? This is the date that the labeler indicates was the start of its marketing of the drug product.
What is the Listing Expiration Date? This is the date when the listing record will expire if not updated or certified by the product labeler.
What is the NDC Exclude Flag? This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions, or because the listing certification is expired, or because the listing data was inactivated by FDA, or because it was discontinued by the labeler. Possible values in this field are: "D", "E", "I", "N", "U".